Newly designed antibodies that bind to small clumps of amyloid-beta may keep the progression of Alzheimer's disease in check.
Researchers have isolated a set of antibodies from a llama which show promise for the treatment of COVID-19. The NIH-CoVnB-112 nanoantibody bound to ACE2 receptors up to ten times stronger than other lab-produced antibodies. The nanoantibody stuck directly to the ACE2 receptor binding portion of the SARS_CoV-2 spike protein. The protein could be effective in preventing coronavirus infection.
While the amount of antibodies generated varies widely in patients who have recovered from coronavirus, most people generate at least some antibodies which are intrinsically capable of neutralizing the SARS-CoV-2 virus.
S309, a neutralizing antibody first identified in blood samples from a patient who recovered from SARS in 2003, shows promise for the treatment of COVID-19.
Using computational methods, researchers created artificial proteins that triggered immune responses and produced infection specific antibodies. The findings indicate it will be possible to design vaccines that contain artificial antibodies, expediting the process of vaccine development.
Recovered coronavirus patients show a wide range of immune responses following the infection, with about half from a current study showing sustained antibodies two weeks later. Results indicate which parts of the virus are most effective at triggering the immune responses.
Researchers have identified a fully human monoclonal antibody that prevents SARS-CoV-2, the virus that causes COVID-19, from infecting cultured cells. The antibody binds to a domain that is conserved in SARS-CoV-2, neutralizing the virus. The findings are an initial step towards developing a fully human antibody to prevent or treat coronavirus.
Researchers are sifting through millions of antibodies produced by those who have recovered from COVID-19 to find which ones neutralize the virus. The team has already identified several antibodies that block coronavirus from interacting with its receptors.
People with OCD have six times higher Immuno-moodulin (Imood) expression that those without the disorder. Blocking Imood with the aid of an antibody reduced OCD-like behaviors in mouse models within a couple of days following treatment.
Researchers have designed antibody-like receptor proteins that can bind to cytokines, possibly reducing the effects of the COVID-19 associated cytokine storm.
Researchers have developed a novel antibody strategy to prevent the association between a harmless protein and a disease mediator that could lead to sepsis, and ultimately death. The findings could help to prevent sepsis induced by COVID-19 infections.
Structural mapping of both SARS and SARS-CoV-2, the virus that causes COVID-19, reveals an almost identical site on both coronaviruses to which the CR3022 antibody binds. This suggests a functionally important and vulnerable site for this family of coronaviruses.
